Pannell William C, Banks Kian, Hahn Joseph, Inaba Kenji, Marecek Geoffrey S
Department of Orthopaedic Surgery, USC, Los Angeles, CA, United States.
Keck School of Medicine at USC, Los Angeles, CA, United States.
Injury. 2016 Mar;47(3):653-7. doi: 10.1016/j.injury.2016.01.018. Epub 2016 Jan 23.
Antibiotic administration during the treatment of open fractures has been shown to reduce infection rates and is considered a critical step in the management of these injuries. The purpose of this study was to determine if aminoglycoside administration during the treatment of open fractures leads to acute kidney injury.
Patient records at a level I trauma centre were reviewed for adult patients who presented in 2014 with open fractures were screened for inclusion. Patients were excluded with fractures of the phalanges, metatarsals, and metacarpals, with isolated traumatic arthrotomies, or pre-existing renal dysfunction. Charts were reviewed for patient age, gender, race, past medical history, medication history, injury severity score, intravenous dye studies and fracture type. Patients were divided into those given cefazolin (Group A) and cefazolin with gentamicin (Group B). Laboratory values were used to determine which patients developed kidney dysfunction as measured using the RIFLE criteria. Wilcoxon-Mann-Whitney test and Chi-square were used to compare interval and categorical variables, respectively. Significance was set at P<0.05.
One-hundred and fifty-nine patients met inclusion criteria. Forty-one (25%) patients were given cefazolin alone and 113 (68%) patients were given cefazolin with gentamicin. Ten (18%) patients with Gustilo-Anderson type III fractures were given cefazolin alone and 67 (67%) patients with types I or II fractures were given a cefazolin with gentamicin. Baseline characteristics and risk factors for renal dysfunction did not vary between groups. Two (4.8%) patients in Group A and 5 (4%) patients in Group B developed acute kidney injury (P=0.599).
Gentamicin use during the treatment of open fractures does not lead to increased rates of renal dysfunction when used in patients with normal baseline renal function.
开放性骨折治疗期间使用抗生素已被证明可降低感染率,被视为这些损伤治疗中的关键步骤。本研究的目的是确定开放性骨折治疗期间使用氨基糖苷类药物是否会导致急性肾损伤。
回顾了一级创伤中心2014年收治的成年开放性骨折患者的病历,以筛选纳入研究。排除指骨、跖骨和掌骨骨折、单纯创伤性关节切开术或既往存在肾功能不全的患者。查阅病历以获取患者的年龄、性别、种族、既往病史、用药史、损伤严重程度评分、静脉造影检查和骨折类型。患者分为接受头孢唑林治疗的组(A组)和接受头孢唑林加庆大霉素治疗的组(B组)。使用实验室值根据RIFLE标准确定哪些患者出现肾功能不全。分别使用Wilcoxon-Mann-Whitney检验和卡方检验比较区间变量和分类变量。显著性设定为P<0.05。
159例患者符合纳入标准。41例(25%)患者仅接受头孢唑林治疗,113例(68%)患者接受头孢唑林加庆大霉素治疗。10例(18%)Gustilo-Anderson III型骨折患者仅接受头孢唑林治疗,67例(67%)I型或II型骨折患者接受头孢唑林加庆大霉素治疗。两组间肾功能不全的基线特征和危险因素无差异。A组2例(4.8%)患者和B组5例(4%)患者发生急性肾损伤(P=0.599)。
在基线肾功能正常的患者中,开放性骨折治疗期间使用庆大霉素不会导致肾功能不全发生率增加。